Singapore markets closed

Aligos Therapeutics, Inc. (ALGS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.6885+0.0335 (+5.11%)
At close: 04:00PM EDT
0.7229 +0.03 (+5.00%)
After hours: 06:03PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 51.16M
Enterprise value -51.09M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.40
Price/book (mrq)0.86
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 2.34
52-week change 3-36.41%
S&P500 52-week change 326.36%
52-week high 31.2200
52-week low 30.5390
50-day moving average 30.8733
200-day moving average 30.7827

Share statistics

Avg vol (3-month) 3402.76k
Avg vol (10-day) 3160.78k
Shares outstanding 575.02M
Implied shares outstanding 678.11M
Float 837.78M
% held by insiders 120.39%
% held by institutions 160.53%
Shares short (15 Apr 2024) 4657.21k
Short ratio (15 Apr 2024) 41.68
Short % of float (15 Apr 2024) 40.96%
Short % of shares outstanding (15 Apr 2024) 40.87%
Shares short (prior month 15 Mar 2024) 4365.6k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-942.67%

Management effectiveness

Return on assets (ttm)-36.63%
Return on equity (ttm)-89.48%

Income statement

Revenue (ttm)15.53M
Revenue per share (ttm)0.24
Quarterly revenue growth (yoy)-24.20%
Gross profit (ttm)N/A
EBITDA -85.84M
Net income avi to common (ttm)-87.68M
Diluted EPS (ttm)-1.3600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)135.7M
Total cash per share (mrq)1.79
Total debt (mrq)11.14M
Total debt/equity (mrq)12.10%
Current ratio (mrq)5.90
Book value per share (mrq)1.23

Cash flow statement

Operating cash flow (ttm)-79M
Levered free cash flow (ttm)-45.91M